Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts—An Alternate Approach to Somatic Gene Therapy

Ayman Al-Hendy, Gonzalo Hortelano, Patricia L. Chang, Gloria S. Tannenbaum, Patricia L. Chang, Patricia L. Chang

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Most of the currently approved human gene therapy protocols depend on genetic modification of autologous cells. We propose an alternate and potentially more cost-effective approach by implanting genetically modified “universal” cell lines to deliver desired gene products to nonautologous recipients. The recombinant allogeneic cells are protected from rejection after implantation by enclosure within immuno-protective alginate-poly-l-lysine-alginate microcapsules. The clinical efficacy of this strategy is now demonstrated by implanting microencapsulated allogeneic myoblasts engineered to secrete mouse growth hormone into the growth hormone-deficient Snell dwarf mice. The treated mutants attained increases in linear growth, body weights, peripheral organ weights, and tibial growth plate thickness significantly greater than those of the untreated controls. Secondary response to the exogenous growth hormone stimulation also resulted in increased fatty acid metabolism during the first month post-implantation. The microcapsules retrieved after about 6 months of implantation appeared intact. The encapsulated myoblasts retained a viability of >60% and continued to secrete mouse growth hormone. Thus, implantation of nonautologous recombinant cells corrected partially the pleiomorphic effects of a transcription factor mutation in the Snell dwarf mice and the encapsulated cells remained functional for at least 6 months. This simple method of delivery recombinant gene products in vivo is a benign procedure, obviates the need for patient-specific genetic modification, and is amenable to industrial-scale quality control. It should have wide applications in therapies requiring a systemic continuous supply of recombinant gene products Overview summary “Nonautologous somatic gene therapeutics” is an alternate approach to somatic gene therapy in which universal cell lines engineered to secrete desired gene products are implanted into different recipients with the same product requirement. To prevent immune rejection of nonautologous cell lines, immuno-protective devices such as microcapsules are used to enclose these cells before implantation. We have succeeded in delivering recombinant gene products such as human growth hormone, human factor IX, and a secretable form of human adenosine deaminase in vitro and in vivo through this technology. We now show that this strategy is clinically effective. By delivering encapsulated myoblasts secreting mouse growth hormone to the growth hormone-deficient Snell dwarf mice, we have been able to enhance growth of these mutants as measured with a variety of physiological parameters. The possibility of delivering biologically active gene products in vivo for extended periods with a benign and potentially cost-effective protocol is useful not only for therapeutic purposes but also for studying developmental biology in some instances as an alternate to the transgenic animal paradigm.

Original languageEnglish (US)
Pages (from-to)165-175
Number of pages11
JournalHuman Gene Therapy
Volume6
Issue number2
DOIs
StatePublished - Feb 1 1995

Fingerprint

Genetic Therapy
Growth Hormone
Growth
Myoblasts
Genes
Capsules
Cell Line
Protective Devices
Costs and Cost Analysis
Developmental Biology
Genetically Modified Animals
Factor IX
Growth Plate
Organ Size
Human Growth Hormone
Quality Control
Lysine
Transcription Factors
Fatty Acids
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts—An Alternate Approach to Somatic Gene Therapy. / Al-Hendy, Ayman; Hortelano, Gonzalo; Chang, Patricia L.; Tannenbaum, Gloria S.; Chang, Patricia L.; Chang, Patricia L.

In: Human Gene Therapy, Vol. 6, No. 2, 01.02.1995, p. 165-175.

Research output: Contribution to journalArticle

Al-Hendy, Ayman ; Hortelano, Gonzalo ; Chang, Patricia L. ; Tannenbaum, Gloria S. ; Chang, Patricia L. ; Chang, Patricia L. / Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts—An Alternate Approach to Somatic Gene Therapy. In: Human Gene Therapy. 1995 ; Vol. 6, No. 2. pp. 165-175.
@article{b84198de2d2e4f8ab014b1ecac1d383c,
title = "Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts—An Alternate Approach to Somatic Gene Therapy",
abstract = "Most of the currently approved human gene therapy protocols depend on genetic modification of autologous cells. We propose an alternate and potentially more cost-effective approach by implanting genetically modified “universal” cell lines to deliver desired gene products to nonautologous recipients. The recombinant allogeneic cells are protected from rejection after implantation by enclosure within immuno-protective alginate-poly-l-lysine-alginate microcapsules. The clinical efficacy of this strategy is now demonstrated by implanting microencapsulated allogeneic myoblasts engineered to secrete mouse growth hormone into the growth hormone-deficient Snell dwarf mice. The treated mutants attained increases in linear growth, body weights, peripheral organ weights, and tibial growth plate thickness significantly greater than those of the untreated controls. Secondary response to the exogenous growth hormone stimulation also resulted in increased fatty acid metabolism during the first month post-implantation. The microcapsules retrieved after about 6 months of implantation appeared intact. The encapsulated myoblasts retained a viability of >60{\%} and continued to secrete mouse growth hormone. Thus, implantation of nonautologous recombinant cells corrected partially the pleiomorphic effects of a transcription factor mutation in the Snell dwarf mice and the encapsulated cells remained functional for at least 6 months. This simple method of delivery recombinant gene products in vivo is a benign procedure, obviates the need for patient-specific genetic modification, and is amenable to industrial-scale quality control. It should have wide applications in therapies requiring a systemic continuous supply of recombinant gene products Overview summary “Nonautologous somatic gene therapeutics” is an alternate approach to somatic gene therapy in which universal cell lines engineered to secrete desired gene products are implanted into different recipients with the same product requirement. To prevent immune rejection of nonautologous cell lines, immuno-protective devices such as microcapsules are used to enclose these cells before implantation. We have succeeded in delivering recombinant gene products such as human growth hormone, human factor IX, and a secretable form of human adenosine deaminase in vitro and in vivo through this technology. We now show that this strategy is clinically effective. By delivering encapsulated myoblasts secreting mouse growth hormone to the growth hormone-deficient Snell dwarf mice, we have been able to enhance growth of these mutants as measured with a variety of physiological parameters. The possibility of delivering biologically active gene products in vivo for extended periods with a benign and potentially cost-effective protocol is useful not only for therapeutic purposes but also for studying developmental biology in some instances as an alternate to the transgenic animal paradigm.",
author = "Ayman Al-Hendy and Gonzalo Hortelano and Chang, {Patricia L.} and Tannenbaum, {Gloria S.} and Chang, {Patricia L.} and Chang, {Patricia L.}",
year = "1995",
month = "2",
day = "1",
doi = "10.1089/hum.1995.6.2-165",
language = "English (US)",
volume = "6",
pages = "165--175",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts—An Alternate Approach to Somatic Gene Therapy

AU - Al-Hendy, Ayman

AU - Hortelano, Gonzalo

AU - Chang, Patricia L.

AU - Tannenbaum, Gloria S.

AU - Chang, Patricia L.

AU - Chang, Patricia L.

PY - 1995/2/1

Y1 - 1995/2/1

N2 - Most of the currently approved human gene therapy protocols depend on genetic modification of autologous cells. We propose an alternate and potentially more cost-effective approach by implanting genetically modified “universal” cell lines to deliver desired gene products to nonautologous recipients. The recombinant allogeneic cells are protected from rejection after implantation by enclosure within immuno-protective alginate-poly-l-lysine-alginate microcapsules. The clinical efficacy of this strategy is now demonstrated by implanting microencapsulated allogeneic myoblasts engineered to secrete mouse growth hormone into the growth hormone-deficient Snell dwarf mice. The treated mutants attained increases in linear growth, body weights, peripheral organ weights, and tibial growth plate thickness significantly greater than those of the untreated controls. Secondary response to the exogenous growth hormone stimulation also resulted in increased fatty acid metabolism during the first month post-implantation. The microcapsules retrieved after about 6 months of implantation appeared intact. The encapsulated myoblasts retained a viability of >60% and continued to secrete mouse growth hormone. Thus, implantation of nonautologous recombinant cells corrected partially the pleiomorphic effects of a transcription factor mutation in the Snell dwarf mice and the encapsulated cells remained functional for at least 6 months. This simple method of delivery recombinant gene products in vivo is a benign procedure, obviates the need for patient-specific genetic modification, and is amenable to industrial-scale quality control. It should have wide applications in therapies requiring a systemic continuous supply of recombinant gene products Overview summary “Nonautologous somatic gene therapeutics” is an alternate approach to somatic gene therapy in which universal cell lines engineered to secrete desired gene products are implanted into different recipients with the same product requirement. To prevent immune rejection of nonautologous cell lines, immuno-protective devices such as microcapsules are used to enclose these cells before implantation. We have succeeded in delivering recombinant gene products such as human growth hormone, human factor IX, and a secretable form of human adenosine deaminase in vitro and in vivo through this technology. We now show that this strategy is clinically effective. By delivering encapsulated myoblasts secreting mouse growth hormone to the growth hormone-deficient Snell dwarf mice, we have been able to enhance growth of these mutants as measured with a variety of physiological parameters. The possibility of delivering biologically active gene products in vivo for extended periods with a benign and potentially cost-effective protocol is useful not only for therapeutic purposes but also for studying developmental biology in some instances as an alternate to the transgenic animal paradigm.

AB - Most of the currently approved human gene therapy protocols depend on genetic modification of autologous cells. We propose an alternate and potentially more cost-effective approach by implanting genetically modified “universal” cell lines to deliver desired gene products to nonautologous recipients. The recombinant allogeneic cells are protected from rejection after implantation by enclosure within immuno-protective alginate-poly-l-lysine-alginate microcapsules. The clinical efficacy of this strategy is now demonstrated by implanting microencapsulated allogeneic myoblasts engineered to secrete mouse growth hormone into the growth hormone-deficient Snell dwarf mice. The treated mutants attained increases in linear growth, body weights, peripheral organ weights, and tibial growth plate thickness significantly greater than those of the untreated controls. Secondary response to the exogenous growth hormone stimulation also resulted in increased fatty acid metabolism during the first month post-implantation. The microcapsules retrieved after about 6 months of implantation appeared intact. The encapsulated myoblasts retained a viability of >60% and continued to secrete mouse growth hormone. Thus, implantation of nonautologous recombinant cells corrected partially the pleiomorphic effects of a transcription factor mutation in the Snell dwarf mice and the encapsulated cells remained functional for at least 6 months. This simple method of delivery recombinant gene products in vivo is a benign procedure, obviates the need for patient-specific genetic modification, and is amenable to industrial-scale quality control. It should have wide applications in therapies requiring a systemic continuous supply of recombinant gene products Overview summary “Nonautologous somatic gene therapeutics” is an alternate approach to somatic gene therapy in which universal cell lines engineered to secrete desired gene products are implanted into different recipients with the same product requirement. To prevent immune rejection of nonautologous cell lines, immuno-protective devices such as microcapsules are used to enclose these cells before implantation. We have succeeded in delivering recombinant gene products such as human growth hormone, human factor IX, and a secretable form of human adenosine deaminase in vitro and in vivo through this technology. We now show that this strategy is clinically effective. By delivering encapsulated myoblasts secreting mouse growth hormone to the growth hormone-deficient Snell dwarf mice, we have been able to enhance growth of these mutants as measured with a variety of physiological parameters. The possibility of delivering biologically active gene products in vivo for extended periods with a benign and potentially cost-effective protocol is useful not only for therapeutic purposes but also for studying developmental biology in some instances as an alternate to the transgenic animal paradigm.

UR - http://www.scopus.com/inward/record.url?scp=0029152724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029152724&partnerID=8YFLogxK

U2 - 10.1089/hum.1995.6.2-165

DO - 10.1089/hum.1995.6.2-165

M3 - Article

VL - 6

SP - 165

EP - 175

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -